Alfacell Corp.

Stephen K. Carter, M.D. has served on our Board of Directors since September 1998. Since 1997, Dr. Carter has been a consultant to the pharmaceutical industry. Dr. Carter was Senior Vice President of Research and Development at Boehringer Ingelheim Pharmaceuticals, Inc. from 1995 to 1997. Prior to joining Boehringer, Dr. Carter was Senior Vice President of Worldwide Clinical Research and Development at Bristol-Myers Squibb Company. From 1976 to 1982, Dr. Carter served as Director of the Northern California Cancer Program. Dr. Carter was also appointed to President Clinton's panel for AIDS drug development. Dr. Carter is a director of Allos Therapeutics, Alfacell Corporation, Emisphere Technologies, Inc. and Vion Pharmaceuticals Inc. and several privately held companies. Dr. Carter received an A.B. in History from Columbia College and an M.D. degree from New York Medical College. He completed a medical internship and residency at Lenox Hill Hospital.

John P. Brancaccio, a retired CPA, has served as a Director of our company since April 2004. Since April 2004, Mr. Brancaccio has been the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. From May 2002 until March 2004, Mr. Brancaccio was the Chief Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company. From 2000 to 2002, Mr. Brancaccio was the Chief Financial Officer/Chief Operating Officer of Eline Group, an entertainment and media company. Mr. Brancaccio is currently a director of Alfacell Corporation as well as a director of each of Xenomics, Inc. and FermaVir Pharmaceuticals, Inc.

Stephen K. Carter, M.D., a Director of the Company since 2003, is the former Senior Vice President, Clinical and Regulatory Affairs, of Sugen, Inc. (ownership of Sugen has since passed to Pfizer, Inc. as part of its acquisition of Pharmacia in April 2003). Dr. Carter previously was the Senior Vice President, Research and Development of Boehringer Ingelheim Pharmaceuticals, Inc., now independently owned. Prior to this, he served 13 years at Bristol-Myers Squibb Co., including, as its Senior Vice President, Worldwide Clinical Research and Development. Dr. Carter is a former Deputy Director at the National Cancer Institute (NCI)'s Division of Cancer Treatment and is a member of the American Society of Clinical Oncology. He received his Medical Doctorate from New York Medical College. He is currently a member of the boards of directors of Alfacell Corporation, Achillion Pharmaceuticals, Inc., Cytogen Corporation, Sopherion Therapeutics, Inc., and Vion Pharmaceuticals, Inc.

Zbigniew Darzynkiewicz, M.D., Ph.D., is the Director of the Brander Cancer Research Institute at the New York Medical College and the Professor of Medicine and Pathology at the same College. Formerly, Dr. Darzynkiewicz was the Professor of Cell Biology and Genetics at Cornell University Medical School, a Member of the Sloan-Kettering Institute for Cancer Research, the Head of the Experimental Cell Research Laboratory, and the Director of the Flow Cytometry Core Facility Network, all at the Sloan-Kettering Institute, New York. Dr. Darzynkiewicz is the Editor of the Experimental Cell Research and Cell Proliferation and a Member of the Editorial Boards of nine other scientific journals. He is the past President of The Cell Kinetics Society and also past President of the International Society for Analytical Cytology (ISAC; with over 2,000 members from over 60 countries). Dr. Darzynkiewicz has authored 400 original publications and over 75 chapters and reviews in books devoted to the subject of cell growth, regulation of the cell cycle and apoptosis, and has authored and/or edited 11 books. He holds five US patents, several are pending. His publications have been cited over 9,000 times in the scientific literature. He consults several pharmaceutical companies and is on the Board of Scientific Advisors of the Alfacell Company (Bloomfield, NJ). Dr. Darzynkiewicz received his M.D. (with highest honors) in 1960 and his Ph.D. in 1966 from the Medical School of Warsaw, Warsaw, Poland. He completed his post-graduate studies at the State University of New York at Buffalo and the Medical Nobel Institute of Karolinska Institute, Stockholm, Sweden. Since 1974, he has been associated with the Sloan-Kettering Institute for Cancer Research, and since 1990, he has been with New York Medical College, Valhalla, New York.